By the time you read this, a handful of countries and organizations have already begun testing their own vaccines, and the FDA is expected to approve a handful more.
It’s an ambitious and risky goal, but it has the potential to radically change the way we think about the prevention and treatment of infectious diseases, including STIs.
It’s also the first step in a larger effort to find a way to deliver vaccines to millions of people who are not already on the waiting list for life-saving treatments.
And it might be the most dramatic one yet.
The challengeThe vaccine is being tested in Africa, South America, Europe and Asia.
It has also been tested in Australia and the United States, as well as in several countries in Europe and the Middle East.
But for the moment, the first clinical trials are happening in the United Kingdom.
The UK is one of a handful that have so far been able to secure a vaccine, according to the UK’s National Institute for Health Research.
The other two are in the Netherlands and Switzerland.
The vaccine was developed at Imperial College London and the vaccine is expected in the coming months.
“The vaccine has to work at the site of infection and not just in the laboratory, and we know it works very well in animals,” said Dr. Chris Jackson, director of the UK Centre for Disease Control and Prevention.
The new vaccine will be tested in the U.K. in three phases.
The first phase will be followed by three more trials in England and Wales.
The second phase will run for three years.
Then, after three more years, the vaccine will reach the U to begin a second phase in the UK.
The vaccine will require around 1 million doses to produce one dose, but that’s expected to be enough to get to around 2.3 million people.
The final vaccine is scheduled to be ready for clinical trials in 2019.
What’s behind the successThe key to this success story is the combination of three factors: vaccines that are cheap, safe and effective.
Vaccines can be made cheaply, and vaccines are highly effective at protecting against HIV and hepatitis C. They’re also cheap to produce, so they can be produced and distributed to anyone with a computer.
In addition, it’s possible to make vaccines inexpensively and deliver them to a large number of people at a fraction of the cost.
There’s no guarantee the first vaccine will succeed.
There are a number of reasons why the U, UK, and other countries haven’t yet been able get a vaccine.
First, the vaccines have not yet been tested.
Second, there’s not yet a vaccine for hepatitis C, which is the virus that causes the disease.
And third, there are many unanswered questions about the efficacy of the vaccine.
Dr. Jackson, who is working on the vaccine, said there are several factors that could be influencing the results of the first phase of the trials.
First and foremost is the success of the vaccines in animals.
In animal trials, the drug is given to mice, which have been treated with the vaccine for months and are able to live with it.
This has been done in a number the U., the U-boat, and in Africa.
But the success has been limited because of the animal trials.
In a clinical trial in humans, the same drug was given to 100 people, but those who received the drug died quickly.
Dr. Jordan Hill, a professor of medicine at the University of California, San Francisco, who has worked on hepatitis C research, said the drug that’s being tested is a compound called AZT, which causes the immune system to attack the virus.
That compound can kill virus, but does not destroy it.
The researchers hope that the drug will be effective in a clinical setting, as long as the drug kills the virus before it kills the person.
“We have to think about it as a drug that kills the infection and the virus,” Dr. Hill said.
“We have not done it yet.
And we haven’t done it in mice yet, either.
So, I’m not sure if that will make a big difference.
We have to wait and see what happens in animals.”
Dr. Hill also said that while there are challenges, there is also some hope.
“The vaccine was not tested in humans yet because there were not enough animals to test it in,” he said.
It is likely that the vaccine won’t be tested with humans.
Another challenge is that the vaccines work well in only a few people.
And even if a person is able to get the vaccine as a second dose, it may not be effective.
Dr. Jackson said that, as a result, it is likely the vaccine would not be as effective in the longer term.Dr